SCHEMBL25215441

SCHEMBL25215441

CC(=O)c1ccc(-c2ccc(NC(=O)OC(C)(C)C)c(N)c2)s1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 6/20 0.42
HSD17B1 P14061 4/20 0.42
HSD17B2 P37059 4/20 0.42
CYP17A1 P05093 1/20 0.42
PGR P06401 1/20 0.41
IKBKE Q14164 1/20 0.40
TBK1 Q9UHD2 1/20 0.40
ERN1 O75460 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAP4K4 O95819 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25242980 0.91 IKBKB (0.44) AAK1HSD17B1HSD17B2CYP17A1MAP4K4
SCHEMBL198874 0.85 HDAC1 (0.49) AAK1CYP17A1IKBKETBK1MAP4K4
SCHEMBL30474668 0.85 HDAC1 (0.49) AAK1CYP17A1IKBKETBK1MAP4K4
SCHEMBL197899 0.84 HDAC2 (0.49) AAK1CYP17A1MAP4K4HDAC3HDAC1
SCHEMBL25212404 0.84 AAK1 (0.45) AAK1HSD17B1HSD17B2CYP17A1MAP4K4
SCHEMBL25242660 0.82 KMT2A (0.42) PGRCYP3A4CYP2C9
SCHEMBL3786645 0.78 AAK1 (0.53) AAK1CYP17A1MAP4K4HDAC1HDAC2
SCHEMBL196444 0.78 HDAC1 (0.59) HDAC3HDAC1HDAC2
SCHEMBL14379419 0.78 NQO2 (0.54) HSD17B1HSD17B2CYP17A1CYP3A4CYP2A6
SCHEMBL29371288 0.78 HDAC1 (0.59) HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
CN-118715206-A Novel HDAC inhibitors and therapeutic uses thereof 探戈医药股份有限公司 2024-09-27 CN disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 AAK1 2510/4885HSD17B1 247/4885HSD17B2 480/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 AAK1 3018/4885HSD17B1 163/4885HSD17B2 294/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 AAK1 3018/4885HSD17B1 163/4885HSD17B2 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.